Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer

The recent approval of olaparib and niraparib as maintenance therapy can significantly affect the management of ovarian cancer. Clinical benefits, however, come with trade-offs in adverse events and costs. To evaluate the cost-effectiveness of new ovarian cancer poly-ADP ribose polymerase (PARP) inh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of managed care & specialty pharmacy 2018-12, Vol.24 (12), p.1219-1228
Hauptverfasser:	Zhong, Lixian, Tran, Anh Thu, Tomasino, Taylor, Nugent, Elizabeth, Smith, Judith A
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Decision-Making - methods Cost-Benefit Analysis Female Health Care Costs Humans Indazoles - economics Indazoles - therapeutic use Models, Economic Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - economics Neoplasm Recurrence, Local - mortality Ovarian Neoplasms - diagnosis Ovarian Neoplasms - drug therapy Ovarian Neoplasms - economics Ovarian Neoplasms - mortality Paclitaxel - pharmacology Paclitaxel - therapeutic use Phthalazines - economics Phthalazines - therapeutic use Piperazines - economics Piperazines - therapeutic use Piperidines - economics Piperidines - therapeutic use Poly(ADP-ribose) Polymerase Inhibitors - economics Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Progression-Free Survival United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!